Taiwan · Delayed Price · Currency is TWD OBI Pharma Statistics
Total Valuation
OBI Pharma has a market cap or net worth of TWD 3.28 billion. The enterprise value is 3.94 billion.
| Market Cap | 3.28B |
| Enterprise Value | 3.94B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OBI Pharma has 131.58 million shares outstanding. The number of shares has increased by 5.05% in one year.
| Current Share Class | 131.58M |
| Shares Outstanding | 131.58M |
| Shares Change (YoY) | +5.05% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.44% |
| Owned by Institutions (%) | 2.14% |
| Float | 86.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.89 |
| PB Ratio | 1.50 |
| P/TBV Ratio | 2.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 75.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.70 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.29 |
| Interest Coverage | -142.21 |
Financial Efficiency
Return on equity (ROE) is -61.67% and return on invested capital (ROIC) is -30.42%.
| Return on Equity (ROE) | -61.67% |
| Return on Assets (ROA) | -29.21% |
| Return on Invested Capital (ROIC) | -30.42% |
| Return on Capital Employed (ROCE) | -66.56% |
| Weighted Average Cost of Capital (WACC) | 4.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 5.75 |
Taxes
| Income Tax | -2.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.30% in the last 52 weeks. The beta is 0.10, so OBI Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -54.30% |
| 50-Day Moving Average | 27.09 |
| 200-Day Moving Average | 38.65 |
| Relative Strength Index (RSI) | 39.56 |
| Average Volume (20 Days) | 309,033 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OBI Pharma had revenue of TWD 52.20 million and -1.53 billion in losses. Loss per share was -11.60.
| Revenue | 52.20M |
| Gross Profit | -79.67M |
| Operating Income | -1.64B |
| Pretax Income | -1.78B |
| Net Income | -1.53B |
| EBITDA | -1.49B |
| EBIT | -1.64B |
| Loss Per Share | -11.60 |
Balance Sheet
The company has 496.96 million in cash and 446.14 million in debt, with a net cash position of 50.82 million or 0.39 per share.
| Cash & Cash Equivalents | 496.96M |
| Total Debt | 446.14M |
| Net Cash | 50.82M |
| Net Cash Per Share | 0.39 |
| Equity (Book Value) | 2.19B |
| Book Value Per Share | 11.30 |
| Working Capital | 614.28M |
Cash Flow
In the last 12 months, operating cash flow was -1.53 billion and capital expenditures -19.43 million, giving a free cash flow of -1.55 billion.
| Operating Cash Flow | -1.53B |
| Capital Expenditures | -19.43M |
| Depreciation & Amortization | 152.19M |
| Net Borrowing | -64.91M |
| Free Cash Flow | -1.55B |
| FCF Per Share | -11.77 |
Margins
| Gross Margin | -152.62% |
| Operating Margin | -3,139.94% |
| Pretax Margin | -3,405.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OBI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.05% |
| Shareholder Yield | -5.05% |
| Earnings Yield | -46.48% |
| FCF Yield | -47.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 27, 2026. It was a reverse split with a ratio of 0.5.
| Last Split Date | Jan 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.5 |
Scores
OBI Pharma has an Altman Z-Score of 1.16 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 1 |